The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Read full article at https://wccftech.com/zealand-amylin-is-the-underdog-that-has-dared-to-challenge-the-might-of-glp-1-weight-loss-drug-heavyweights/
WccftechContinue reading/original-link]
